Display options
Cite
Manser CN, Borovicka J, Seibold F, et al. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J. 2016;4(2):281-7doi: 10.1177/2050640615627533.
Manser, C. N., Borovicka, J., Seibold, F., Vavricka, S. R., Lakatos, P. L., Fried, M., Rogler, G. (2016). Risk factors for complications in patients with ulcerative colitis. United European gastroenterology journal, 4(2), 281-7. https://doi.org/10.1177/2050640615627533
Manser, Christine N, et al. "Risk factors for complications in patients with ulcerative colitis." United European gastroenterology journal vol. 4,2 (2016): 281-7. doi: https://doi.org/10.1177/2050640615627533
Manser CN, Borovicka J, Seibold F, Vavricka SR, Lakatos PL, Fried M, Rogler G. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J. 2016 Apr;4(2):281-7. doi: 10.1177/2050640615627533. Epub 2016 Jan 19. PMID: 27087958; PMCID: PMC4804379.
Copy Download .nbib Format: NLM
Share it on

United European Gastroenterol J. 2016 Apr;4(2):281-7. doi: 10.1177/2050640615627533. Epub 2016 Jan 19.

Risk factors for complications in patients with ulcerative colitis.

United European gastroenterology journal

Christine N Manser, Jan Borovicka, Frank Seibold, Stephan R Vavricka, Peter L Lakatos, Michael Fried, Gerhard Rogler,

Affiliations

  1. Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; Division of Gastroenterology, See-Spital Horgen, Horgen, Switzerland.
  2. Department of Gastroenterology and Hepatology, Kantonsspital St Gallen, Switzerland.
  3. Crohn-Colitis Centre Bern-Fribourg, Switzerland.
  4. Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; Department of Gastroenterology and Hepatology, Triemlispital, Zurich, Switzerland.
  5. 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
  6. Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

PMID: 27087958 PMCID: PMC4804379 DOI: 10.1177/2050640615627533

Abstract

BACKGROUND: Patients with ulcerative colitis may develop extraintestinal manifestations like erythema nodosum or primary sclerosing cholangitis or extraintestinal complications like anaemia, malabsorption or they may have to undergo surgery.

OBJECTIVE: The aim of this study was to investigate potential risk factors for complications like anaemia, malabsorption or surgery in ulcerative colitis.

METHODS: Data on 179 patients with ulcerative colitis were retrieved from our cross-sectional and prospective Swiss Inflammatory Bowel Disease Cohort Study data base for a median observational time of 4.2 years. Data were compared between patients with (n = 140) or without (n = 39) complications. Gender, age at diagnosis, smoking status, disease extent, delay of diagnosis or therapy, mesalamine (5-ASA) systemic and topical therapy, as well as other medication were analysed as potential impact factors.

RESULTS: In the multivariate regression analysis a delay of 5-ASA treatment by at least two months (odds ratio (OR) 6.21 (95% confidence interval (CI) 2.13-18.14), p = 0.001) as well as a delay with other medication with thiopurines (OR 6.48 (95% CI 2.01-20.91), p = 0.002) were associated with a higher risk for complications. This significant impact of a delay of 5-ASA therapy was demonstrated for extraintestinal manifestations (EIMs) as well as extraintestinal complications (EICs). Extensive disease as well as therapy with methotrexate showed a significantly increased risk for surgery (extensive disease: OR 2.62 (1.02-6.73), p = 0.05, methotrexate: OR 5.36 (1.64-17.58), p = 0.006).

CONCLUSIONS: A delay of 5-ASA therapy of more than two months in the early stage of ulcerative colitis (UC) constitutes a risk for complications during disease course. Extensive disease is associated with a higher risk for surgery.

Keywords: Ulcerative colitis; complication; extraintestinal manifestation; mesalamine; risk factor

References

  1. Am J Gastroenterol. 2005 Nov;100(11):2478-85 - PubMed
  2. Am J Gastroenterol. 2007 Apr;102(4):829-36 - PubMed
  3. Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):585-95 - PubMed
  4. PLoS One. 2014 Apr 07;9(4):e94208 - PubMed
  5. Gut. 1990 Mar;31(3):329-33 - PubMed
  6. Inflamm Bowel Dis. 2011 Dec;17(12):2558-65 - PubMed
  7. Dig Dis. 2012;30 Suppl 2:55-9 - PubMed
  8. Am J Gastroenterol. 2013 Jun;108(6):1015 - PubMed
  9. Gastroenterology. 2013 Nov;145(5):996-1006 - PubMed
  10. Am J Gastroenterol. 2013 Nov;108(11):1744-53; quiz 1754 - PubMed
  11. Am J Gastroenterol. 2011 Apr;106(4):731-6 - PubMed
  12. Inflamm Bowel Dis. 2012 Mar;18(3):496-505 - PubMed
  13. Curr Gastroenterol Rep. 2001 Dec;3(6):477-83 - PubMed
  14. Am J Gastroenterol. 2005 Jun;100(6):1345-53 - PubMed
  15. Gastroenterology. 1979 Oct;77(4 Pt 2):914-20 - PubMed
  16. Int J Epidemiol. 2009 Aug;38(4):922-31 - PubMed
  17. Can J Gastroenterol. 2007 Dec;21(12):827-34 - PubMed
  18. J Crohns Colitis. 2012 Dec;6(10):991-1030 - PubMed
  19. Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40 - PubMed
  20. Am J Gastroenterol. 2009 Feb;104(2):371-83 - PubMed
  21. Am J Gastroenterol. 2011 Jan;106(1):110-9 - PubMed
  22. Gastroenterology. 1992 Nov;103(5):1444-51 - PubMed
  23. Gastroenterology. 2007 Feb;132(2):507-15 - PubMed
  24. Inflamm Bowel Dis. 2015 Aug;21(8):1982-92 - PubMed
  25. Scand J Gastroenterol. 2014 Feb;49(2):177-83 - PubMed
  26. Scand J Gastroenterol. 2009;44(4):431-40 - PubMed
  27. World J Gastroenterol. 2003 Oct;9(10):2300-7 - PubMed
  28. Inflamm Bowel Dis. 2004 May;10(3):207-14 - PubMed
  29. Aliment Pharmacol Ther. 2015 Jan;41(1):87-98 - PubMed

Publication Types